Early-Stop trial tests malaria drug for COVID-19

NCT ID NCT04345692

Summary

This study aimed to see if adding the drug hydroxychloroquine to standard hospital care helped adults with COVID-19 get better faster. It compared patients who received the drug for five days to those who received only usual care. The trial was stopped early after enrolling only 17 of a planned 350 patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Queen's Medical Center

    Honolulu, Hawaii, 96813, United States

Conditions

Explore the condition pages connected to this study.